 The study will include three separate periods: Screening Period, Treatment Period up to 48 hours and Follow-up Period up to 7 days or hospital discharge, whichever occurs first representing approximately a maximum of 7 days on study. Eligible patients will be enrolled to receive clevidipine IV antihypertensive treatment study drug in an open label manner. 